University of Alberta spotlights diclofenac foam; clinical evidence comes from small 2020 study
A November 16 interview describes FoamaDerm’s development and commercial use. Its linked clinical study followed 11 patients and had no randomized comparison group.
In this article & details
A University of Alberta researcher is describing how a microemulsion foam developed at the university reached Canadian compounding pharmacies, while the clinical evidence linked to the product remains a small observational study.
In a November 16 Folio interview, pharmacy professor Raimar Löbenberg said his team developed FoamaDerm after questions from an insurer about drug release from compounded diclofenac products. The university’s Drug Development and Innovation Center worked on the formulation, and Löbenberg and colleagues established RS Therapeutics to commercialize it.
Foam base is already sold to pharmacies
The university describes a water-and-coconut-oil microemulsion delivered by a propellant-free foaming pump. Löbenberg said it dissolves the active ingredient without the grinding, solvents or specialized equipment used for some other compounded preparations.
Folio reports that the base is sold to pharmacies across Canada and that the company has established a North Carolina laboratory while pursuing U.S. availability. The November article is an interview about that work, rather than an announcement of a new randomized trial.
Clinical report followed 11 patients
The linked BMC Research Notes study was published in June 2020. Thirteen adults with musculoskeletal pain enrolled, and two were lost to follow-up. Among the remaining 11, nine reported a reduction of at least 50% in pain scores after two weeks using 2% diclofenac in microemulsion foam. Two reported minimal improvement.
No adverse effects were reported during the short follow-up. The study had no randomized control group, and its authors identified the small sample and observational design as limitations. Those findings do not establish comparative clinical superiority over other topical products or rule out uncommon harms.
Löbenberg’s account of improved drug release concerns formulation performance. The linked laboratory research and the small patient series answer different questions; faster release in a laboratory is not itself a large comparative clinical outcome.
The university says the team intends to continue testing the foam as a delivery option for medicines beyond diclofenac.
References
- U of A-developed nanotechnology product delivers topical pain relief faster for chronic conditions like arthritis — University of Alberta — Folio, November 16, 2026 interview
- Determination of efficacy and toxicity of diclofenac microemulsion formulation for musculoskeletal pain: an observational study — BMC Research Notes — Hoan Linh Banh and Andrew Cave, June 12, 2020; background clinical evidence, not a new trial
- Evaluation of a microemulsion-based gel formulation for topical drug delivery of diclofenac sodium — Journal of Pharmaceutical Investigation, Background formulation research